Trial · NCT07277881
The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia
NCT07277881, Phase 4, Not yet recruiting, Medical University of Gdansk
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia. Trials, record NCT07277881. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07277881
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effect of Reversal of Remimazolam Sedation With Flumazenil on Cognitive Function in Patients Undergoing Hip Arthroplasty Under Spinal Anesthesia
- NCT number
- NCT07277881
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 150 participants, estimated
- Lead sponsor
- Medical University of Gdansk
- Conditions
- Postoperative Delirium, Sedation, Remimazolam, Hip Arthroplasty, Total
- Interventions
- remimazolam sedation reversal with flumazenil, placebo
- First posted
- 2025-12-11
- Last updated
- 2026-01-06
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Montreal Cognitive Assessment (MoCA) score | from baseline (preoperative) to 24 hours after surgery | The MoCA is a cognitive screening tool. The total score ranges from 0 to 30 points. A higher score indicates better cognitive function. |
| Secondary | Incidence of delirium (defined as a score of ≥ 4 on the 4AT scale) | within the first 48 hours after surgery, assessed every 6 hours. | |
| Secondary | Total duration of delirium episodes in hours | within the first 48 hours after surgery | |
| Secondary | Preoperative Anxiety Level assessed by Amsterdam Preoperative Anxiety and Information Scale (APAIS) | baseline (preoperative) | The Amsterdam Preoperative Anxiety and Information Scale (APAIS) is a questionnaire consisting of 6 items graded on a 5-point Likert scale (ranging from 1 = "not at all" to 5 = "extremely"). The total score ranges from 6 to 30. A higher score indicates higher levels of preoperative anxiety. |
| Secondary | Montreal Cognitive Assessment (MoCA) score | at 1 and 6 hours after surgery | The MoCA is a cognitive screening tool. The total score ranges from 0 to 30 points. A higher score indicates better cognitive function. |
| Secondary | Mini Montreal Cognitive Assessment (mini-MoCA) scores (telephone assessment) | at 3 and 6 months after surgery | mini-MoCA is an abbreviated version of the MoCA used for remote assessment. The total score usually ranges from 0 to 15 points. A higher score indicates better cognitive function. |
| Secondary | Quality of Recovery-15 (QoR-15) Questionnaire Score | at 24 hours after surgery | The QoR-15 is a patient-reported outcome measure assessing the quality of recovery after anesthesia and surgery. The total score ranges from 0 to 150. A higher score indicates a better quality of recovery. |
| Secondary | The duration of hospital stay | Assessed up to 30 days post-surgery (or through hospital discharge, whichever occurs first). | measured in days from the date of surgery to the date of hospital discharge. |
| Secondary | Maximum and average pain intensity measured by Numeric Rating Scale (NRS) at the following time points | 6, 12, 24, and 48 hours after surgery | Pain intensity will be assessed using the Numeric Rating Scale (NRS). The scale ranges from 0 to 10, where 0 indicates "no pain" and 10 indicates "worst pain imaginable". |
| Secondary | Total oxycodone consumption (in mg) | during the first 48 hours after surgery |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07277881
GET https://conductscience.org/api/trials/v1/NCT07277881/registered